Alternative Data for Summit Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 87 | Sign up | Sign up | Sign up |
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | N/A | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 110 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,587 | Sign up | Sign up | Sign up |
| X Followers | 2,282 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 285 | Sign up | Sign up | Sign up |
About Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI).
| Price | $17.04 |
| Target Price | Sign up |
| Volume | 2,010,000 |
| Market Cap | $13.1B |
| Year Range | $16.19 - $29.32 |
| Dividend Yield | 0% |
| PE Ratio | 26.36 |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 11 - SeekingAlpha |
|
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference TranscriptDecember 3 - SeekingAlpha |
|
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptDecember 2 - SeekingAlpha |
|
Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 TranscriptNovember 17 - SeekingAlpha |
|
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 TranscriptNovember 10 - SeekingAlpha |
 |
Summit Therapeutics to Present at Upcoming Investor ConferencesNovember 3 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -232M | 0 | -0.232 |
| Q2 '25 | 0 | 42,000 | -42,000 | -232M | -232M | -0.120 |
| Q1 '25 | 0 | 25,000 | -25,000 | -63M | -63M | -0.068 |
| Q4 '24 | 0 | 15M | -15M | -61M | -61M | -0.070 |
| Q3 '24 | 0 | 20,000 | -20,000 | -56M | -54M | -0.080 |
Insider Transactions View All
| DUGGAN ROBERT W filed to buy 76,680 shares at $18.7. October 23 '25 |
| Zanganeh Mahkam filed to buy 76,680 shares at $18.7. October 23 '25 |
| Xia Yu filed to buy 32,057,147 shares at $18.7. October 23 '25 |
| DUGGAN ROBERT W filed to buy 556,093,090 shares at $18.1. September 11 '25 |
| Zanganeh Mahkam filed to buy 556,093,090 shares at $18.1. September 11 '25 |
Similar companies
Read more about Summit Therapeutics (SMMT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Summit Therapeutics
The Market Cap of Summit Therapeutics is $13.1B.
As of today, Summit Therapeutics' PE (Price to Earnings) ratio is 26.36.
Currently, the price of one share of Summit Therapeutics stock is $17.04.
The SMMT stock price chart above provides a comprehensive visual representation of Summit Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Summit Therapeutics shares. Our platform offers an up-to-date SMMT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Summit Therapeutics (SMMT) does not offer dividends to its shareholders. Investors interested in Summit Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Summit Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
